company background image
JANX logo

Janux Therapeutics NasdaqGM:JANX Stock Report

Last Price

US$56.14

Market Cap

US$2.9b

7D

-5.8%

1Y

437.7%

Updated

24 Dec, 2024

Data

Company Financials +

Janux Therapeutics, Inc.

NasdaqGM:JANX Stock Report

Market Cap: US$2.9b

JANX Stock Overview

A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. More details

JANX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Janux Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Janux Therapeutics
Historical stock prices
Current Share PriceUS$56.14
52 Week HighUS$71.71
52 Week LowUS$7.79
Beta3.29
1 Month Change11.59%
3 Month Change17.23%
1 Year Change437.74%
3 Year Change166.32%
5 Year Changen/a
Change since IPO123.22%

Recent News & Updates

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Dec 03

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Recent updates

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Dec 03

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Shareholder Returns

JANXUS BiotechsUS Market
7D-5.8%-3.3%-0.4%
1Y437.7%-2.7%24.8%

Return vs Industry: JANX exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: JANX exceeded the US Market which returned 23.9% over the past year.

Price Volatility

Is JANX's price volatile compared to industry and market?
JANX volatility
JANX Average Weekly Movement15.8%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: JANX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: JANX's weekly volatility has decreased from 35% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201776David Campbellwww.januxrx.com

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products.

Janux Therapeutics, Inc. Fundamentals Summary

How do Janux Therapeutics's earnings and revenue compare to its market cap?
JANX fundamental statistics
Market capUS$2.95b
Earnings (TTM)-US$60.54m
Revenue (TTM)US$13.05m

225.8x

P/S Ratio

-48.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JANX income statement (TTM)
RevenueUS$13.05m
Cost of RevenueUS$59.82m
Gross Profit-US$46.77m
Other ExpensesUS$13.76m
Earnings-US$60.54m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.15
Gross Margin-358.45%
Net Profit Margin-463.91%
Debt/Equity Ratio0%

How did JANX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:19
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Janux Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Kaveri PohlmanBTIG
Justin ZelinBTIG